209 related articles for article (PubMed ID: 36292115)
1. A Study of Biomarkers Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes.
Efrem IC; Moța M; Vladu IM; Mitrea A; Clenciu D; Timofticiuc DCP; Diaconu ID; Turcu A; Crișan AE; Geormăneanu C; Glodeanu AD; Mahler B; Tudor MS; Amzolini AM; Micu SE; Barău Abu Alhija A; Mită A; Filip MM; Forțofoiu M
Diagnostics (Basel); 2022 Oct; 12(10):. PubMed ID: 36292115
[TBL] [Abstract][Full Text] [Related]
2. Prediction and Validation of Metabolic Dysfunction-Associated Fatty Liver Disease Using Insulin Resistance-Related Indices in the Japanese Population.
Moriyama K; Inoue N; Imai J; Masuda Y; Yamada C; Kishimoto N; Takashimizu S; Kubo A; Nishizaki Y
Metab Syndr Relat Disord; 2023 Nov; 21(9):489-496. PubMed ID: 37878804
[No Abstract] [Full Text] [Related]
3. Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study.
Liu Z; He H; Dai Y; Yang L; Liao S; An Z; Li S
Lipids Health Dis; 2022 Jun; 21(1):55. PubMed ID: 35752830
[TBL] [Abstract][Full Text] [Related]
4. Elevated small dense low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with an increased risk of metabolic dysfunction associated fatty liver disease in Chinese patients with type 2 diabetes mellitus.
Yang S; Xu J
J Diabetes Investig; 2024 May; 15(5):634-642. PubMed ID: 38251808
[TBL] [Abstract][Full Text] [Related]
5. [Application of TG/HDL-C Combined with Liver Function Indexes to Predict Metabolic-Associated Fatty Liver Disease].
Xia JX; Zhao YH; He H; Liang SS; Gan W; Li GX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):764-769. PubMed ID: 36224676
[TBL] [Abstract][Full Text] [Related]
6. GA/HbA1c ratio is a simple and practical indicator to evaluate the risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: an observational study.
Wang JW; Jin CH; Ke JF; Ma YL; Wang YJ; Lu JX; Li MF; Li LX
Diabetol Metab Syndr; 2022 Nov; 14(1):167. PubMed ID: 36369095
[TBL] [Abstract][Full Text] [Related]
7. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study.
Wang JW; Jin CH; Ke JF; Ma YL; Wang YJ; Lu JX; Li MF; Li LX
Front Endocrinol (Lausanne); 2022; 13():942412. PubMed ID: 36133303
[TBL] [Abstract][Full Text] [Related]
8. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents.
Chin J; Mori TA; Adams LA; Beilin LJ; Huang RC; Olynyk JK; Ayonrinde OT
JHEP Rep; 2020 Dec; 2(6):100150. PubMed ID: 32984791
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.
Samimi S; Rajabzadeh S; Rabizadeh S; Nakhjavani M; Nakhaei P; Avanaki FA; Esteghamati A
Eur J Med Res; 2022 Jul; 27(1):112. PubMed ID: 35818084
[TBL] [Abstract][Full Text] [Related]
10. Perirenal Fat Thickness is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus.
Yang J; Li CW; Zhang JR; Qiu H; Guo XL; Wang W
Diabetes Metab Syndr Obes; 2023; 16():1953-1965. PubMed ID: 37405319
[TBL] [Abstract][Full Text] [Related]
11. Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study.
Ma YL; Ke JF; Wang JW; Wang YJ; Xu MR; Li LX
Front Endocrinol (Lausanne); 2023; 14():1133991. PubMed ID: 37223022
[TBL] [Abstract][Full Text] [Related]
12. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
Ye J; Zhuang X; Li X; Gong X; Sun Y; Wang W; Feng S; Wu T; Zhong B
Metabolism; 2022 Nov; 136():155294. PubMed ID: 35995280
[TBL] [Abstract][Full Text] [Related]
13. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
14. Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus.
Gao Q; Feng L; Zhou W; Li X; Yin L; Wang Y
Diabetes Metab Syndr Obes; 2023; 16():2345-2354. PubMed ID: 37577041
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
16. The difference in correlation between insulin resistance index and chronic inflammation in type 2 diabetes with and without metabolic syndrome.
Pourfarzam M; Zadhoush F; Sadeghi M
Adv Biomed Res; 2016; 5():153. PubMed ID: 27713874
[TBL] [Abstract][Full Text] [Related]
17. Decreased Serum Osteocalcin is an Independent Risk Factor for Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes.
Wang YJ; Jin CH; Ke JF; Wang JW; Ma YL; Lu JX; Li MF; Li LX
Diabetes Metab Syndr Obes; 2022; 15():3717-3728. PubMed ID: 36471670
[TBL] [Abstract][Full Text] [Related]
18. Monocyte to High-Density Lipoprotein Cholesterol Ratio at the Nexus of Type 2 Diabetes Mellitus Patients With Metabolic-Associated Fatty Liver Disease.
Jia J; Liu R; Wei W; Yu F; Yu X; Shen Y; Chen C; Cai Z; Wang C; Zhao Z; Wang D; Yang L; Yuan G
Front Physiol; 2021; 12():762242. PubMed ID: 34975521
[No Abstract] [Full Text] [Related]
19. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes.
Mantovani A; Csermely A; Taverna A; Cappelli D; Benfari G; Bonapace S; Byrne CD; Targher G
Diabetes Metab; 2023 Mar; 49(2):101416. PubMed ID: 36586476
[TBL] [Abstract][Full Text] [Related]
20. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in nonobese patients without type 2 diabetes mellitus.
Liu J; Wang C; Wang YT; Liu JX; Zhou TH; Yao SK; Chen G
Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E62-E71. PubMed ID: 37285598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
